This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences Management

Management criteria checks 4/4

Key information

Dave Marek

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage12.0%
CEO tenure2.2yrs
CEO ownership0.1%
Management average tenure4.3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Not The Buyout Offer That Myovant Shareholders Hoped For

Oct 25

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Oct 03

Women Can Thank Pfizer And Myovant For MYFEMBREE

Sep 20

Myovant Sciences: Regulatory Overhang Cleared

Aug 29

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28
Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Myovant Sciences: Becoming A Blockbuster

Jun 02

Myovant Sciences rises on FDA approval for relugolix

May 26

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14
Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment

May 09

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17
New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13
Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12
Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’

Jan 06

Myovant Sciences announces distribution of ORGOVYX in the U.S.

Jan 05

Myovant Sciences gains 22% on relugolix deal with Pfizer

Dec 28

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23
Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Myovant Sciences’ FDA win leads to Bullish views at Baird

Dec 21

Myovant Sciences scores FDA approval for Orgovyx in prostate cancer

Dec 18

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18
Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Myovant Sciences: More Than Meets The Eye

Nov 12

The Sell-Off In Myovant Is Unjustified By Fundamentals

Nov 09

CEO Compensation Analysis

How has Dave Marek's remuneration changed compared to Myovant Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022n/an/a

-US$184m

Sep 30 2022n/an/a

-US$190m

Jun 30 2022n/an/a

-US$166m

Mar 31 2022US$6mUS$750k

-US$206m

Dec 31 2021n/an/a

-US$228m

Sep 30 2021n/an/a

-US$238m

Jun 30 2021n/an/a

-US$284m

Mar 31 2021US$10mUS$151k

-US$255m

Compensation vs Market: Dave's total compensation ($USD6.25M) is about average for companies of similar size in the US market ($USD6.53M).

Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.


CEO

Dave Marek (57 yo)

2.2yrs

Tenure

US$6,247,509

Compensation

Mr. David C. Marek, also known as Dave, has been Director of Myovant Sciences Ltd. since January 4, 2021 and served as its Principal Executive Officer. He had been Chief Commercial Officer of Axsome Therap...


Leadership Team

NamePositionTenureCompensationOwnership
David Marek
CEO & Director2.2yrsUS$6.25m0.098%
$ 2.6m
Uneek Mehra
Principal Financial Officer1.5yrsUS$5.16m0.021%
$ 559.0k
Lauren Merendino
Chief Commercial Officer1.9yrsUS$3.47m0.022%
$ 587.9k
Matthew Lang
General Counsel & Corporate Secretary5.7yrsUS$2.83m0.36%
$ 9.6m
Albert Liao
Director of Corporate Communicationsno datano datano data
Ann Tomlin
Senior Vice President of Human Resourcesless than a yearno datano data
Bryan Selby
Senior Vice President of Product Development6.6yrsno datano data
Juan Camilo Ferreira
Chief Medical Officer5.7yrsUS$1.98m0.089%
$ 2.3m
Andria Langenberg
Head of Drug Safety & Pharmacovigilance5.7yrsno datano data
Jeffrey Nornhold
Senior VP of Pharmaceutical Operations & Development4.3yrsno datano data

4.3yrs

Average Tenure

52yo

Average Age

Experienced Management: MYOV's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
David Marek
CEO & Director2.2yrsUS$6.25m0.098%
$ 2.6m
Myrtle Potter
Chairman of the Board4.5yrsUS$376.79k0%
$ 0
Terrie Curran
Independent Director6.3yrsUS$363.33k0%
$ 0
Adele Gulfo
Director3.3yrsUS$341.79k0%
$ 0
Mark Guinan
Lead Independent Director4.7yrsUS$369.95k0%
$ 0
Shigeyuki Nishinaka
Non Independent Directorless than a yearno datano data
Nancy Valente
Independent Director1.3yrsUS$567.05k0%
$ 0

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: MYOV's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.